Reducing Overdose After Release From Incarceration (ROAR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The primary objective of the ROAR project is to evaluate an Oregon Department of Corrections (ODOC) pilot program that combines the use of extended-release naltrexone (XR-NTX) and Certified Recovery Mentors pre-release with linkage to community substance use disorder treatment to prevent fatal and non-fatal opioid overdoses among female adults released from prison.
Condition or disease
Other: XR-NTX and Certified Recovery Mentor
ROAR examines implementation of a novel overdose prevention strategy for justice-involved women as they re-enter community treatment settings after incarceration. The ODOC pilot project offers initiation of opioid antagonist treatment prior to release (extended-release naltrexone [XR-NTX]), ongoing support from a Certified Recovery Mentor (CRM), and facilitated entry into community treatment for substance use disorders. Community treatment may include continuation of XR-NTX,or transition to agonist therapy including buprenorphine or methadone, or no medication for opioid use disorder.
All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 100 Years (Adult, Older Adult)
Sexes Eligible for Study:
Gender Based Eligibility:
Gender Eligibility Description:
Study sample is composed of women including transgender and non-binary adults assigned to women's housing at Coffee Creek Correctional Facility.
Accepts Healthy Volunteers:
The study will directly recruit incarcerated adult females who meet the DSM-V criteria for moderate or severe opioid use disorder. All participants will have a scheduled release date to Marion, Multnomah, Washington, or Clackamas County, Oregon.
Be a woman (including transgenderand non-binary adults assigned to women's housing at CCCF)
18 years of age or older with a known release date during the 18-month recruitment period
Be released to Marion, Multnomah, Clackamas or Washington County, Oregon
Be willing and able to provide informed consent and HIPAA authorization for medical record abstraction and linkage to state administrative data
Meet DSM-V criteria for moderate or severe opioid use disorder
Be willing to establish ongoing care at the community SUD treatment site in county of release
Be willing to initiate XR-NTX prior to release from incarceration
Not be currently pregnant and must be willing to take at least one evidence-based measure to avoid becoming pregnant during treatment with XR-NTX
Exclusion Criteria: A participant will be excluded if she
Has a severe medical, psychiatric,or substance use disorder that, in the opinion of the CCCFQualified Mental Health Professional (QMHP)or study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study due to imminent risk of death
Has another medical condition leading XR-NTX to be contraindicated
Has chronic pain requiring ongoing pain management with opioid analgesics
Received methadone or buprenorphine maintenance therapy in the 4 weeks prior to consent
Has a planned surgery or other procedure within the next 4 weeks that will require opioid analgesia